Opiant Pharmaceuticals Inc (NASDAQ:OPNT) major shareholder Geoffrey Wolf sold 2,570 shares of the company’s stock in a transaction on Friday, December 8th. The stock was sold at an average price of $30.40, for a total value of $78,128.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) traded down $4.78 on Thursday, hitting $24.11. The stock had a trading volume of 167,800 shares, compared to its average volume of 36,180. Opiant Pharmaceuticals Inc has a 12-month low of $5.00 and a 12-month high of $51.90. The stock has a market cap of $59.74, a price-to-earnings ratio of 68.79 and a beta of -2.33.

Opiant Pharmaceuticals (NASDAQ:OPNT) last issued its quarterly earnings data on Monday, December 4th. The technology company reported ($2.77) EPS for the quarter, missing the consensus estimate of ($1.19) by ($1.58). Opiant Pharmaceuticals had a net margin of 8.93% and a return on equity of 42.44%. The business had revenue of $0.02 million for the quarter. equities research analysts forecast that Opiant Pharmaceuticals Inc will post -5.12 earnings per share for the current year.

Several analysts have recently commented on OPNT shares. ValuEngine upgraded Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. TheStreet upgraded Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a report on Monday, October 16th.

TRADEMARK VIOLATION NOTICE: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/12/14/geoffrey-wolf-sells-2570-shares-of-opiant-pharmaceuticals-inc-opnt-stock.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.